MacroGenics flags press release on MGC026 Phase 1 study update
MGNX•Enrollment, safety and presentation plans
As of July 8, 2026, 74 patients were enrolled; no interstitial lung disease or ocular toxicity was reported.
Interim Phase 1 results were accepted for an ESMO 2026 poster presentation on Oct. 23 in Madrid.
Phase 1 update on MGC026 in advanced solid tumors
MacroGenics posted a clinical update on its Phase 1 study of MGC026, a B7-H3-directed ADC, in advanced solid tumors.
Dose escalation tested 1-9 mg/kg every three weeks; 7.5 mg/kg is being evaluated in four tumor-specific cohorts.
The head and neck squamous cell carcinoma cohort met the Stage 1 response bar; Stage 2 enrollment is underway under Simon’s two-stage design.
